Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT01678872

A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

A Long Term Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

Status
Active Not Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
18 (estimated)
Sponsor
Oxford BioMedica · Industry
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.

Conditions

Interventions

TypeNameDescription
DRUGRetinoStatLong Term Follow up of patients who received RetinoStat in a previous study

Timeline

Start date
2012-08-01
Primary completion
2029-03-01
Completion
2029-03-01
First posted
2012-09-05
Last updated
2026-01-14

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01678872. Inclusion in this directory is not an endorsement.

A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration (NCT01678872) · Clinical Trials Directory